{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:17:37Z","timestamp":1790727457010,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T00:00:00Z","timestamp":1715385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T00:00:00Z","timestamp":1715385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Immunol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Thyroid eye disease (TED) is an inflammatory process involving lymphocyte-mediated immune response and orbital tissue damage. The anti-insulin-like growth factor-1 receptor (IGF-1R) antibodies produced by B lymphocytes are involved in the activation of orbital fibroblasts and the inflammatory process of orbital tissue damage in TED. The purpose of this study was to explore the role of IGF-1R in the mechanistic connection between orbital fibroblasts and B lymphocytes in TED.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Orbital fibroblasts sampled from orbital connective tissues and peripheral B lymphocytes isolated from peripheral blood, which were obtained from 15 patients with TED and 15 control patients, were co-cultured at a ratio of 1:20. The level of IGF-1R expression in orbital fibroblasts was evaluated by flow cytometry and confocal microscopy. Transient B lymphocyte depletion was induced with anti-CD20 monoclonal antibody rituximab, while the IGF-1R pathway was blocked by the IGF-1R binding protein. The expression levels of interleukin-6 (IL-6) and regulated upon activation, normal T cell expressed and secreted (RANTES) in the co-culture model were quantified via ELISA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>IGF-1R expression was significantly elevated in TED orbital fibroblasts compared to that of controls. A 24-h co-culture of orbital fibroblasts with peripheral B lymphocytes induced elevated expression levels of IL-6 and RANTES in each group (TED patients and controls), with the highest levels occurring in TED patients (T\u2009+\u2009T group). Rituximab and IGF-1R binding protein significantly inhibited increased levels of IL-6 and RANTES in the co-culture model of TED patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>IGF-1R may mediate interaction between orbital fibroblasts and peripheral B lymphocytes; thus, blocking IGF-1R may reduce the local inflammatory response in TED. Rituximab-mediated B lymphocyte depletion played a role in inhibiting inflammatory responses in this in vitro co-culture model, providing a theoretical basis for the clinical application of anti-CD20 monoclonal antibodies in TED.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12865-024-00613-3","type":"journal-article","created":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T07:01:51Z","timestamp":1715410911000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Potential role of IGF-1R in the interaction between orbital fibroblasts and B lymphocytes: an implication for B lymphocyte depletion in the active inflammatory phase of thyroid-associated ophthalmopathy"],"prefix":"10.1186","volume":"25","author":[{"given":"Renyan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,11]]},"reference":[{"key":"613_CR1","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/MED.0b013e32830eb8ab","volume":"15","author":"AG Gianoukakis","year":"2008","unstructured":"Gianoukakis AG, Smith TJ. Recent insights into the pathogenesis and management of thyroid-associated ophthalmopathy. Curr Opin Endocrinol Diabetes Obes. 2008;15:446\u201352.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"613_CR2","doi-asserted-by":"publisher","first-page":"7453260","DOI":"10.1155\/2019\/7453260","volume":"2019","author":"D \u0141acheta","year":"2019","unstructured":"\u0141acheta D, Mi\u015bkiewicz P, G\u0142uszko A, Nowicka G, Struga M, Kantor I, et al. Immunological aspects of Graves\u2019 Ophthalmopathy. Biomed Res Int. 2019;2019:7453260.","journal-title":"Biomed Res Int"},{"key":"613_CR3","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/bph.13693","volume":"174","author":"RF Place","year":"2017","unstructured":"Place RF, Krieger CC, Neumann S, Gershengorn MC. Inhibiting thyrotropin\/insulin-like growth factor 1 receptor crosstalk to treat Graves\u2019 ophthalmopathy: studies in orbital fibroblasts in vitro. Br J Pharmacol. 2017;174:328\u201340.","journal-title":"Br J Pharmacol"},{"key":"613_CR4","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","volume":"376","author":"TJ Smith","year":"2017","unstructured":"Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, et al. Teprotumumab for thyroid-Associated Ophthalmopathy. N Engl J Med. 2017;376:1748\u201361.","journal-title":"N Engl J Med"},{"key":"613_CR5","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41433-018-0285-y","volume":"33","author":"M Salvi","year":"2019","unstructured":"Salvi M, Covelli D. B cells in Graves\u2019 Orbitopathy: more than just a source of antibodies? Eye (Lond). 2019;33:230\u20134.","journal-title":"Eye (Lond)"},{"key":"613_CR6","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1210\/jc.2014-3566","volume":"100","author":"CC Krieger","year":"2015","unstructured":"Krieger CC, Neumann S, Place RF, Marcus-Samuels B, Gershengorn MC. Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves\u2019 disease immunoglobins. J Clin Endocrinol Metab. 2015;100:1071\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"613_CR7","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1210\/en.2005-1375","volume":"147","author":"AG Gianoukakis","year":"2006","unstructured":"Gianoukakis AG, Douglas RS, King CS, Cruikshank WW, Smith TJ. Immunoglobulin G from patients with Graves\u2019 disease induces interleukin-16 and RANTES expression in cultured human thyrocytes: a putative mechanism for T-cell infiltration of the thyroid in autoimmune disease. Endocrinology. 2006;147:1941\u20139.","journal-title":"Endocrinology"},{"key":"613_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","volume":"47","author":"MP Mourits","year":"1997","unstructured":"Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves\u2019 ophthalmopathy. Clin Endocrinol (Oxf). 1997;47:9\u201314.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"613_CR9","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/S0161-6420(96)30744-6","volume":"103","author":"GB Bartley","year":"1996","unstructured":"Bartley GB. The differential diagnosis and classification of eyelid retraction. Ophthalmology. 1996;103:168\u201376.","journal-title":"Ophthalmology"},{"key":"613_CR10","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/EJE-21-0479","volume":"185","author":"L Bartalena","year":"2021","unstructured":"Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, et al. The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. Eur J Endocrinol. 2021;185:G43\u201367.","journal-title":"Eur J Endocrinol"},{"key":"613_CR11","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.3892\/etm.2021.10781","volume":"22","author":"ML Macovei","year":"2021","unstructured":"Macovei ML, Azis \u0170, Gheorghe AG, Burcea M. A systematic review of Euthyroid Graves\u2019 disease (review). Exp Ther Med. 2021;22:1346.","journal-title":"Exp Ther Med"},{"key":"613_CR12","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/374546a0","volume":"374","author":"AM Krieg","year":"1995","unstructured":"Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995;374:546\u20139.","journal-title":"Nature"},{"key":"613_CR13","doi-asserted-by":"crossref","unstructured":"J\u00f3zefiak A, Larska M, Pomorska-M\u00f3l M, Ruszkowski JJ. The IGF-1 signaling pathway in viral infections. Viruses. 2021;13.","DOI":"10.3390\/v13081488"},{"key":"613_CR14","first-page":"5886","volume":"24","author":"RS Chen","year":"2020","unstructured":"Chen RS, Zhang XB, Zhu XT, Wang CS. The crosstalk between IGF-1R and ER-\u03b1 in the proliferation and anti-inflammation of nucleus pulposus cells. Eur Rev Med Pharmacol Sci. 2020;24:5886\u201394.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"613_CR15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.bcp.2017.12.009","volume":"149","author":"T Shuang","year":"2018","unstructured":"Shuang T, Fu M, Yang G, Wu L, Wang R. The interaction of IGF-1\/IGF-1R and hydrogen sulfide on the proliferation of mouse primary vascular smooth muscle cells. Biochem Pharmacol. 2018;149:143\u201352.","journal-title":"Biochem Pharmacol"},{"key":"613_CR16","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s12253-018-0493-6","volume":"25","author":"B Xie","year":"2019","unstructured":"Xie B, Nie S, Hu G, Xiong L, Hu F, Li M, et al. The involvement of NF-\u03baB\/Klotho signaling in Colorectal Cancer Cell Survival and Invasion. Pathol Oncol Res. 2019;25:1553\u201365.","journal-title":"Pathol Oncol Res"},{"key":"613_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1210\/en.2005-1018","volume":"147","author":"R Han","year":"2006","unstructured":"Han R, Smith TJ. T helper type 1 and type 2 cytokines exert divergent influence on the induction of prostaglandin E2 and hyaluronan synthesis by interleukin-1beta in orbital fibroblasts: implications for the pathogenesis of thyroid-associated ophthalmopathy. Endocrinology. 2006;147:13\u20139.","journal-title":"Endocrinology"},{"key":"613_CR18","doi-asserted-by":"publisher","first-page":"5076","DOI":"10.1210\/jc.2004-0716","volume":"89","author":"TJ Smith","year":"2004","unstructured":"Smith TJ, Hoa N. Immunoglobulins from patients with Graves\u2019 disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metab. 2004;89:5076\u201380.","journal-title":"J Clin Endocrinol Metab"},{"key":"613_CR19","doi-asserted-by":"crossref","unstructured":"Gontarz-Nowak K, Szychli\u0144ska M, Matuszewski W, Stefanowicz-Rutkowska M, Bandurska-Stankiewicz E. Current Knowledge on Graves\u2019 Orbitopathy. J Clin Med. 2020;10.","DOI":"10.3390\/jcm10010016"},{"key":"613_CR20","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","volume":"382","author":"RS Douglas","year":"2020","unstructured":"Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, et al. Teprotumumab for the treatment of active thyroid Eye Disease. N Engl J Med. 2020;382:341\u201352.","journal-title":"N Engl J Med"},{"key":"613_CR21","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/j.1600-0463.2007.apm_682a.x","volume":"115","author":"E Waaler","year":"2007","unstructured":"Waaler E. On the occurrence of a factor in human serum activating the specific agglutintion of sheep blood corpuscles. 1939. APMIS. 2007;115:422\u201338. discussion 39.","journal-title":"APMIS"},{"key":"613_CR22","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1530\/eje.1.02119","volume":"154","author":"M Salvi","year":"2006","unstructured":"Salvi M, Vannucchi G, Campi I, Rossi S, Bonara P, Sbrozzi F, et al. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur J Endocrinol. 2006;154:511\u20137.","journal-title":"Eur J Endocrinol"},{"key":"613_CR23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1530\/eje.1.02325","volume":"156","author":"M Salvi","year":"2007","unstructured":"Salvi M, Vannucchi G, Campi I, Curr\u00f2 N, Dazzi D, Simonetta S, et al. Treatment of Graves\u2019 disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol. 2007;156:33\u201340.","journal-title":"Eur J Endocrinol"},{"key":"613_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2265.2010.03806.x","volume":"74","author":"L Heged\u00fcs","year":"2011","unstructured":"Heged\u00fcs L, Smith TJ, Douglas RS, Nielsen CH. Targeted biological therapies for Graves\u2019 disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab. Clin Endocrinol (Oxf). 2011;74:1\u20138.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"613_CR25","doi-asserted-by":"publisher","first-page":"1079852","DOI":"10.3389\/fendo.2022.1079852","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang Y, Hu H, Chen L, Zhang H, Yang T, Xu X, et al. Observation study of using a small dose of rituximab treatment for thyroid-associated ophthalmopathy in seven Chinese patients: one pilot study. Front Endocrinol (Lausanne). 2022;13:1079852.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"613_CR26","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12886-018-0679-4","volume":"18","author":"C Wang","year":"2018","unstructured":"Wang C, Ning Q, Jin K, Xie J, Ye J. Does Rituximab improve clinical outcomes of patients with thyroid-associated ophthalmopathy? A systematic review and meta-analysis. BMC Ophthalmol. 2018;18:46.","journal-title":"BMC Ophthalmol"}],"container-title":["BMC Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-024-00613-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12865-024-00613-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-024-00613-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T07:02:15Z","timestamp":1715410935000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcimmunol.biomedcentral.com\/articles\/10.1186\/s12865-024-00613-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,11]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["613"],"URL":"https:\/\/doi.org\/10.1186\/s12865-024-00613-3","relation":{},"ISSN":["1471-2172"],"issn-type":[{"value":"1471-2172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,11]]},"assertion":[{"value":"4 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board Committee of Peking Union Medical College Hospital, and was performed in accordance with the Declaration of Helsinki. A written informed consent was obtained from each subject.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}